Rolf Jan Rutten

Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France.

Citryll BV is a private pharmaceutical company located in Oss, the Netherlands, at the Pivot Park. Citryll is dedicated to developing and commercializing therapeutics that target netosis and NETs, with a focus on immune-mediated inflammatory diseases. The Dutch company's lead antibody, Cit-013, has a unique dual mode of action and proprietary NET biomarker assays, making it a promising drug for rheumatoid arthritis and hidradenitis suppurativa. The initial clinical trials with Cit-013 are expected to provide the foundation for a new treatment paradigm for immune-mediated inflammatory diseases. The company was founded in 2015 by Helmuth van Es, Renato Chirivi, and the late Jos Raats of ModiQuest.